Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
(NASDAQ: FULC) Delayed: 3.77 +0.07 (1.89%)
Previous Close $3.70    52 Week High $ 
Open $3.69    52 Week Low $ 
Day High $3.89    P/E N/A 
Day Low $3.63    EPS $ 
Volume 2,868,623